Bio-Techne (TECH) Other Non-Current Liabilities (2014 - 2026)
Bio-Techne's quarterly Other Non-Current Liabilities came in at $21.7 million in Q1 2026, up 38.4% year-on-year from $15.7 million in Q1 2025, and down 6.11% quarter-over-quarter from $23.1 million in Q4 2025.
Bio-Techne has reported Other Non-Current Liabilities for 13 years, with the latest figure at $21.7 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 38.4% year-over-year to $21.7 million; the trailing twelve-month figure through Mar 2026 stood at $21.7 million (up 38.4% YoY), and the FY2025 full-year result was $27.1 million, up 105.84% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $21.7 million, down from $23.1 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $27.1 million in Q2 2025, with the low at $4.8 million in Q1 2022.
- Average Other Non-Current Liabilities over 5 years is $14.8 million, with a median of $12.2 million recorded in 2022.
- Year-over-year, Other Non-Current Liabilities tumbled 40.41% in 2022 and jumped 148.01% in 2023.
- Tracing TECH's Other Non-Current Liabilities over 5 years: stood at $7.0 million in 2022, then soared by 148.01% to $17.4 million in 2023, then slumped by 34.7% to $11.3 million in 2024, then soared by 103.56% to $23.1 million in 2025, then declined by 6.11% to $21.7 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $21.7 million (Q1 2026), $23.1 million (Q4 2025), and $23.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Bio-Techne | 7.92 Bn | 7.71 Bn | 208.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.67 Mn |
| Dec 31, 2025 | 23.08 Mn |
| Sep 30, 2025 | 23.81 Mn |
| Jun 30, 2025 | 27.08 Mn |
| Mar 31, 2025 | 15.66 Mn |
| Dec 31, 2024 | 11.34 Mn |
| Sep 30, 2024 | 19.79 Mn |
| Jun 30, 2024 | 13.16 Mn |
| Mar 31, 2024 | 11.56 Mn |
| Dec 31, 2023 | 17.36 Mn |
| Sep 30, 2023 | 9.39 Mn |
| Jun 30, 2023 | 10.92 Mn |
| Mar 31, 2023 | 10.97 Mn |
| Dec 31, 2022 | 7.00 Mn |
| Sep 30, 2022 | 11.50 Mn |
| Jun 30, 2022 | 12.24 Mn |
| Mar 31, 2022 | 4.80 Mn |
| Dec 31, 2021 | 11.75 Mn |
| Sep 30, 2021 | 17.60 Mn |
| Jun 30, 2021 | 18.30 Mn |
| Mar 31, 2021 | 7.10 Mn |
| Dec 31, 2020 | 25.80 Mn |
| Sep 30, 2020 | 29.98 Mn |
| Jun 30, 2020 | 26.95 Mn |
| Mar 31, 2020 | 1.70 Mn |
| Dec 31, 2019 | 2.68 Mn |
| Sep 30, 2019 | 5.13 Mn |
| Jun 30, 2019 | 25.22 Mn |
| Mar 31, 2019 | 19.50 Mn |
| Dec 31, 2018 | 17.99 Mn |
| Sep 30, 2018 | 9.67 Mn |
| Jun 30, 2018 | 9.34 Mn |
| Mar 31, 2018 | 9.14 Mn |
| Dec 31, 2017 | 53.30 Mn |
| Sep 30, 2017 | 40.90 Mn |
| Jun 30, 2017 | 68.40 Mn |
| Mar 31, 2017 | 4.40 Mn |
| Dec 31, 2016 | 28.60 Mn |
| Sep 30, 2016 | 3.65 Mn |
| Jun 30, 2016 | 38.50 Mn |
| Mar 31, 2016 | 3.16 Mn |
| Dec 31, 2015 | 3.22 Mn |
| Sep 30, 2015 | 3.15 Mn |
| Jun 30, 2015 | 3.20 Mn |
| Mar 31, 2015 | 35.00 Mn |
| Dec 31, 2014 | 35,000.00 |
| Sep 30, 2014 | 708,000.00 |